RHONEMA Stock Overview
Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia.
Rhone Ma Holdings Berhad Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||RM0.69|
|52 Week High||RM0.79|
|52 Week Low||RM0.67|
|1 Month Change||1.47%|
|3 Month Change||-4.83%|
|1 Year Change||0%|
|3 Year Change||-4.17%|
|5 Year Change||-36.75%|
|Change since IPO||-12.76%|
Recent News & Updates
Rhone Ma Holdings Berhad (KLSE:RHONEMA) Has Announced A Dividend Of RM0.01
Rhone Ma Holdings Berhad's ( KLSE:RHONEMA ) investors are due to receive a payment of RM0.01 per share on 15th of July...
|RHONEMA||MY Pharmaceuticals||MY Market|
Return vs Industry: RHONEMA exceeded the MY Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: RHONEMA exceeded the MY Market which returned -3.4% over the past year.
|RHONEMA Average Weekly Movement||4.1%|
|Pharmaceuticals Industry Average Movement||3.9%|
|Market Average Movement||5.5%|
|10% most volatile stocks in MY Market||11.7%|
|10% least volatile stocks in MY Market||2.7%|
Stable Share Price: RHONEMA is not significantly more volatile than the rest of MY stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: RHONEMA's weekly volatility (4%) has been stable over the past year.
About the Company
Rhone Ma Holdings Berhad, an investment holding company, engages in the manufacture, trading, marketing, and distribution of animal health products primarily in Malaysia. It operates through Animal Health Products, Food Ingredients, and Others segments. The company provides diagnostic laboratory analysis and consultation services to veterinary, agriculture, and food industries; veterinary advisory services; and distributes pharmaceutical and veterinary products, including animal feeds.
Rhone Ma Holdings Berhad Fundamentals Summary
|RHONEMA fundamental statistics|
Is RHONEMA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RHONEMA income statement (TTM)|
|Cost of Revenue||RM124.95m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.053|
|Net Profit Margin||6.58%|
How did RHONEMA perform over the long term?See historical performance and comparison
2.9%Current Dividend Yield
Is RHONEMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 5/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for RHONEMA?
Other financial metrics that can be useful for relative valuation.
|What is RHONEMA's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does RHONEMA's PE Ratio compare to its peers?
|RHONEMA PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
YSPSAH Y.S.P. Southeast Asia Holding Berhad
PLABS PeterLabs Holdings Berhad
KOTRA Kotra Industries Berhad
DPHARMA Duopharma Biotech Berhad
RHONEMA Rhone Ma Holdings Berhad
Price-To-Earnings vs Peers: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the peer average (13.6x).
Price to Earnings Ratio vs Industry
How does RHONEMA's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?
Price-To-Earnings vs Industry: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the MY Pharmaceuticals industry average (14x)
Price to Earnings Ratio vs Fair Ratio
What is RHONEMA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||13x|
|Fair PE Ratio||15.3x|
Price-To-Earnings vs Fair Ratio: RHONEMA is good value based on its Price-To-Earnings Ratio (13x) compared to the estimated Fair Price-To-Earnings Ratio (15.3x).
Share Price vs Fair Value
What is the Fair Price of RHONEMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: RHONEMA (MYR0.69) is trading below our estimate of fair value (MYR1.19)
Significantly Below Fair Value: RHONEMA is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is less than 20% higher than the current share price.
Discover undervalued companies
How is Rhone Ma Holdings Berhad forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RHONEMA's earnings are forecast to decline over the next 3 years (-3.7% per year).
Earnings vs Market: RHONEMA's earnings are forecast to decline over the next 3 years (-3.7% per year).
High Growth Earnings: RHONEMA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: RHONEMA's revenue (4.1% per year) is forecast to grow slower than the MY market (5.3% per year).
High Growth Revenue: RHONEMA's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RHONEMA's Return on Equity is forecast to be low in 3 years time (7.1%).
Discover growth companies
How has Rhone Ma Holdings Berhad performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RHONEMA has high quality earnings.
Growing Profit Margin: RHONEMA's current net profit margins (6.6%) are higher than last year (5.3%).
Past Earnings Growth Analysis
Earnings Trend: RHONEMA's earnings have declined by 5% per year over the past 5 years.
Accelerating Growth: RHONEMA's earnings growth over the past year (46.6%) exceeds its 5-year average (-5% per year).
Earnings vs Industry: RHONEMA earnings growth over the past year (46.6%) exceeded the Pharmaceuticals industry 21.4%.
Return on Equity
High ROE: RHONEMA's Return on Equity (8.3%) is considered low.
Discover strong past performing companies
How is Rhone Ma Holdings Berhad's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: RHONEMA's short term assets (MYR106.2M) exceed its short term liabilities (MYR25.1M).
Long Term Liabilities: RHONEMA's short term assets (MYR106.2M) exceed its long term liabilities (MYR27.0M).
Debt to Equity History and Analysis
Debt Level: RHONEMA has more cash than its total debt.
Reducing Debt: RHONEMA's debt to equity ratio has increased from 4.6% to 20.3% over the past 5 years.
Debt Coverage: RHONEMA's debt is well covered by operating cash flow (38.8%).
Interest Coverage: RHONEMA's interest payments on its debt are well covered by EBIT (14.9x coverage).
Discover healthy companies
What is Rhone Ma Holdings Berhad current dividend yield, its reliability and sustainability?
Dividend Score 2/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: RHONEMA's dividend (2.9%) is higher than the bottom 25% of dividend payers in the MY market (2%).
High Dividend: RHONEMA's dividend (2.9%) is low compared to the top 25% of dividend payers in the MY market (4.82%).
Stability and Growth of Payments
Stable Dividend: RHONEMA has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: RHONEMA has only been paying a dividend for 5 years, and since then payments have fallen.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (34.5%), RHONEMA's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (129.2%), RHONEMA's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
I-Ie Lim (51 yo)
Dr. Ban Keong Lim, also known as I-Ie, serves as Group Managing Director of Rhone Ma Holdings Berhad and has been its Executive Director since April 1, 2015. Dr. Lim is responsible for the overall manageme...
CEO Compensation Analysis
Compensation vs Market: I-Ie's total compensation ($USD188.16K) is above average for companies of similar size in the MY market ($USD112.38K).
Compensation vs Earnings: I-Ie's compensation has increased by more than 20% in the past year.
Experienced Board: RHONEMA's board of directors are considered experienced (7.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.
Rhone Ma Holdings Berhad's employee growth, exchange listings and data sources
- Name: Rhone Ma Holdings Berhad
- Ticker: RHONEMA
- Exchange: KLSE
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: RM152.646m
- Shares outstanding: 221.23m
- Website: https://www.rhonema.com
Number of Employees
- Rhone Ma Holdings Berhad
- Lot 18A & 18B
- Jalan 241
- Petaling Jaya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/12 00:00|
|End of Day Share Price||2022/08/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.